Form 4: Cytokinetics EVP Fady Ibraham Malik Executes Stock Option and Sells Shares

Fady Ibraham Malik, EVP of Research & Development at Cytokinetics, exercised stock options and sold a portion of the acquired shares on March 4, 2025.

Summary

• On March 4, 2025, Fady Ibraham Malik, the EVP of Research & Development at Cytokinetics Inc., executed a non-qualified stock option to purchase 2,000 shares of common stock at a price of $10.60 per share.
• Simultaneously, Malik sold 2,000 shares of Cytokinetics common stock at a price of $42.50 per share.
• Following these transactions, Malik directly owns 116,071 shares of Cytokinetics common stock.
• Malik also directly owns 31,105 non-qualified stock options.

Sentiment

Score: 5

Explanation: Neutral sentiment as it is a standard Form 4 filing detailing stock transactions. The transactions themselves don't necessarily indicate a positive or negative outlook.

Industry Context

Executive stock transactions are common and are closely watched by investors as they can provide insights into an executive's perspective on the company's future prospects. This transaction is a routine disclosure.

Stakeholder Impact

• The transaction may have a minor impact on shareholders due to the change in ownership, but it is unlikely to be significant given the relatively small number of shares involved.

Key Dates